Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCLI NASDAQ:MAAQ NASDAQ:RNTX NASDAQ:XCUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$0.74-5.5%$0.81$0.52▼$4.55$8.13M0.15570,613 shs6,650 shsMAAQMana Capital Acquisition$3.63-2.2%$3.93$5.35▼$10.25$29.49MN/A33,075 shs29,985 shsRNTXRein Therapeutics$1.19-9.2%$1.31$1.04▼$4.40$27.73M1.1357,668 shs91,601 shsXCURExicure$3.82-8.0%$6.66$1.44▼$36.00$24.14M3.8472,280 shs38,850 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics+11.32%+2.10%+34.45%-37.12%-81.23%MAAQMana Capital Acquisition-2.16%-4.72%+5.22%-25.00%+1,151.72%RNTXRein Therapeutics-2.24%-2.96%+18.02%-32.82%+130,999,900.00%XCURExicure-3.49%-24.13%-44.30%-55.57%+139.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$0.74-5.5%$0.81$0.52▼$4.55$8.13M0.15570,613 shs6,650 shsMAAQMana Capital Acquisition$3.63-2.2%$3.93$5.35▼$10.25$29.49MN/A33,075 shs29,985 shsRNTXRein Therapeutics$1.19-9.2%$1.31$1.04▼$4.40$27.73M1.1357,668 shs91,601 shsXCURExicure$3.82-8.0%$6.66$1.44▼$36.00$24.14M3.8472,280 shs38,850 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics+11.32%+2.10%+34.45%-37.12%-81.23%MAAQMana Capital Acquisition-2.16%-4.72%+5.22%-25.00%+1,151.72%RNTXRein Therapeutics-2.24%-2.96%+18.02%-32.82%+130,999,900.00%XCURExicure-3.49%-24.13%-44.30%-55.57%+139.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics 2.00HoldN/AN/AMAAQMana Capital Acquisition 0.00N/AN/AN/ARNTXRein Therapeutics 2.00HoldN/AN/AXCURExicure 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BCLI, RNTX, MAAQ, and XCUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025RNTXRein TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold7/23/2025BCLIBrainstorm Cell TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.36) per shareN/AMAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/A$0.40 per share2.99$0.43 per shareN/AXCURExicure$500K48.28N/AN/A$1.12 per share3.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$11.62M-$3.10N/AN/AN/AN/AN/A-519.50%11/13/2025 (Estimated)MAAQMana Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ARNTXRein Therapeutics-$62.88M-$2.69N/AN/AN/AN/A-141.11%-33.83%N/AXCURExicure-$9.70M-$3.88N/A∞N/AN/A-192.16%-84.30%11/12/2025 (Estimated)Latest BCLI, RNTX, MAAQ, and XCUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RNTXRein Therapeutics-$0.22-$0.28-$0.06-$0.28N/AN/A8/8/2025Q2 2025XCURExicureN/A-$0.41N/A-$0.41N/AN/A6/27/2025Q1 2025XCURExicureN/A-$0.45N/A$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/AMAAQMana Capital AcquisitionN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/AXCURExicureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.210.21MAAQMana Capital AcquisitionN/AN/AN/ARNTXRein TherapeuticsN/A0.860.86XCURExicureN/A1.891.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%MAAQMana Capital Acquisition68.44%RNTXRein Therapeutics90.89%XCURExicure42.82%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics11.15%MAAQMana Capital AcquisitionN/ARNTXRein Therapeutics5.10%XCURExicure8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics4011.04 million8.74 millionOptionableMAAQMana Capital Acquisition18.13 millionN/ANot OptionableRNTXRein Therapeutics923.31 million22.12 millionN/AXCURExicure506.32 million5.79 millionNot OptionableBCLI, RNTX, MAAQ, and XCUR HeadlinesRecent News About These CompaniesExicure, Inc. (NASDAQ:XCUR) Short Interest Down 52.4% in AugustSeptember 7 at 3:09 AM | americanbankingnews.comExicure Posts Wider Loss in Fiscal Q2August 8, 2025 | aol.comAExicure, Inc. Reports Second Quarter 2025 Financial Results | XCUR Stock NewsAugust 8, 2025 | gurufocus.comExicure, Inc. Reports Second Quarter 2025 Financial ResultsAugust 8, 2025 | businesswire.comExicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing RequirementsAugust 4, 2025 | businesswire.comStocks to Watch: Exicure, TTECAugust 3, 2025 | marketwatch.comExicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous TransplantAugust 1, 2025 | businesswire.comXCUR | Exicure Inc. Annual Cash Flow Statement - MarketWatchJuly 19, 2025 | marketwatch.comIs Exicure Stock (XCUR) Experiencing a Dead Cat Bounce?June 30, 2025 | msn.comExicure Shares Up After Swing to Profit in 1QJune 27, 2025 | marketwatch.comExicure, Inc. Reports First Quarter 2025 Financial ResultsJune 27, 2025 | businesswire.comExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-QMay 28, 2025 | businesswire.comWhy Exicure Inc. (XCUR) Soared on MondayApril 22, 2025 | msn.comExicure’s subsidiary, GPCR Therapeutics doses 19th patient in its phase 2 study of GPC-100 in multiple myelomaApril 16, 2025 | pharmabiz.comPExicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100April 15, 2025 | pharmabiz.comPExicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple MyelomaApril 14, 2025 | businesswire.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...April 11, 2025 | gurufocus.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | investing.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | businesswire.comWednesday’s Insider Moves: Top Buys and Sells in US StocksMarch 27, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCLI, RNTX, MAAQ, and XCUR Company DescriptionsBrainstorm Cell Therapeutics NASDAQ:BCLI$0.74 -0.04 (-5.48%) As of 02:35 PM EasternBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Mana Capital Acquisition NASDAQ:MAAQ$3.63 -0.08 (-2.16%) As of 09/8/2025Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.Rein Therapeutics NASDAQ:RNTX$1.19 -0.12 (-9.16%) As of 02:55 PM EasternRein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.Exicure NASDAQ:XCUR$3.82 -0.33 (-7.95%) As of 03:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
